Exclusive Summary

• High-Potential Bio-better: A second-generation, highly selective JAK1 inhibitor explicitly benchmarking Upadacitinib, with Phase I newly completed for IBD.
• Superior Safety Design: engineered with 17-fold selectivity for JAK1 over JAK2 (vs. 4.4-fold for Upadacitinib), significantly reducing the risk of myelosuppression and hematologic toxicity.
• De-risked Asset: The molecule boasts established Proof of Concept (PoC) with strong Phase II/III efficacy and safety data in sister indications (Atopic Dermatitis & Ankylosing Spondylitis), minimizing development risk for IBD.
• Significant Market Opportunity: Targets the multi-billion dollar global autoimmune market with a convenient oral dosage form, offering superior compliance over injectable biologics.

Asset Materials

Contact Us for Full Materials